Literature DB >> 16103613

High rates of apoptosis in human Mycobacterium ulcerans culture-positive buruli ulcer skin lesions.

Douglas S Walsh1, Wayne M Meyers, Francoise Portaels, Joshua E Lane, Duangrat Mongkolsirichaikul, Kittinun Hussem, Panita Gosi, Khin Saw Aye Myint.   

Abstract

Buruli ulcer, a disease caused by Mycobacterium ulcerans, causes ulcerative skin disease likely generated by a toxin that mediates apoptosis. We analyzed paraffin-embedded sections of surgically excised Buruli ulcer lesions (two ulcers and one edematous plaque) and adjacent non-lesional skin samples (n = 9) for apoptosis by an indirect immunofluorescent terminal deoxynucleotide transferase-mediated dUTP-digoxigenin nick end labeling (TUNEL) assay. All samples were stained for acid-fast bacilli (AFB) and cultured for mycobacteria, and most were analyzed with an M. ulcerans-specific diagnostic polymerase chain reaction (PCR). TUNEL (+) bodies were numerous in both ulcers and the plaque, and sparse or absent in adjacent non-lesional skin. The AFB tissue stains and cultures for M. ulcerans were positive only in the three lesions. The result of the PCR for M. ulcerans was positive in all three lesions and in four of six non-lesional tissue samples; three contained sparse TUNEL (+) bodies. An abundance of TUNEL (+) bodies in the three AFB stain (+), culture (+), and PCR (+) Buruli ulcer lesional samples, but not in nearby AFB stain (-), culture (-), and PCR (+) non-lesional skin samples, strengthen the evidence that apoptosis is an important tissue destruction mechanism in human lesions closely associated with viable M. ulcerans.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16103613

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  8 in total

Review 1.  Buruli Ulcer, a Prototype for Ecosystem-Related Infection, Caused by Mycobacterium ulcerans.

Authors:  Dezemon Zingue; Amar Bouam; Roger B D Tian; Michel Drancourt
Journal:  Clin Microbiol Rev       Date:  2017-12-13       Impact factor: 26.132

2.  Mycolactone is responsible for the painlessness of Mycobacterium ulcerans infection (buruli ulcer) in a murine study.

Authors:  Junichiro En; Masamichi Goto; Kazue Nakanaga; Michiyo Higashi; Norihisa Ishii; Hajime Saito; Suguru Yonezawa; Hirofumi Hamada; Pamela L C Small
Journal:  Infect Immun       Date:  2008-03-03       Impact factor: 3.441

Review 3.  Buruli ulcer disease: prospects for a vaccine.

Authors:  Kris Huygen; Ohene Adjei; Dissou Affolabi; Gisela Bretzel; Caroline Demangel; Bernhard Fleischer; Roch Christian Johnson; Jorge Pedrosa; Delphin M Phanzu; Richard O Phillips; Gerd Pluschke; Vera Siegmund; Mahavir Singh; Tjip S van der Werf; Mark Wansbrough-Jones; Françoise Portaels
Journal:  Med Microbiol Immunol       Date:  2009-02-07       Impact factor: 3.402

4.  BCG-mediated protection against Mycobacterium ulcerans infection in the mouse.

Authors:  Paul J Converse; Deepak V Almeida; Eric L Nuermberger; Jacques H Grosset
Journal:  PLoS Negl Trop Dis       Date:  2011-03-15

5.  Genotyping Tools for Mycobacterium ulcerans-Drawbacks and Future Prospects.

Authors:  Charles A Narh; Lydia Mosi; Charles Quaye; Samuel Ck Tay; Bassirou Bonfoh; Dziedzom K de Souza
Journal:  Mycobact Dis       Date:  2014-05-05

Review 6.  Bacterial Toxins as Pathogen Weapons Against Phagocytes.

Authors:  Ana do Vale; Didier Cabanes; Sandra Sousa
Journal:  Front Microbiol       Date:  2016-02-01       Impact factor: 5.640

7.  Detection of Mycolactone A/B in Mycobacterium ulcerans-Infected Human Tissue.

Authors:  Fred Stephen Sarfo; Richard O Phillips; Brian Rangers; Engy A Mahrous; Richard E Lee; Edward Tarelli; Kingsley B Asiedu; Pamela L Small; Mark H Wansbrough-Jones
Journal:  PLoS Negl Trop Dis       Date:  2010-01-05

Review 8.  Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease.

Authors:  Fred Stephen Sarfo; Richard Phillips; Mark Wansbrough-Jones; Rachel E Simmonds
Journal:  Cell Microbiol       Date:  2016-01       Impact factor: 3.715

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.